Open access
Aug 2026
TLSB-25 SINGLE-CELL CHARACTERIZATION OF RENAL CELL CARCINOMA BRAIN METASTASIS
RCC BM represents a biologically distinct tumor entity shaped by neural adaptation, metabolic reprogramming, and immune dysfunction, and supported clinical trials approval testing lenvatinib plus pembrolizumab and zanzalitinib in RCC BM patients.
M. I. Ali, Z. Akpinar, Jose A. Ovando-Ricardez et al.
· Neuro-Oncology Advances · 0 citations